发明名称 |
Method of treatment based on polymorphisms of the KCNQ1 gene |
摘要 |
The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation. |
申请公布号 |
US9157121(B2) |
申请公布日期 |
2015.10.13 |
申请号 |
US201514632914 |
申请日期 |
2015.02.26 |
申请人 |
Vanda Pharmaceuticals, Inc. |
发明人 |
Wolfgang Curt D.;Polymeropoulos Mihael H. |
分类号 |
C12Q1/68;C12P19/34;A61K31/454 |
主分类号 |
C12Q1/68 |
代理机构 |
Hoffman Warnick LLC |
代理人 |
Hoffman Warnick LLC |
主权项 |
1. A method of administering iloperidone or a metabolite thereof to treating a human individual the method comprising:
determining or having determined the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 ; and in the case that the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, administering to the individual a first quantity of iloperidone or a metabolite thereof, and in the case that the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 is not associated with an increased risk of QT prolongation, administering to the individual a second quantity of iloperidone or a metabolite thereof, wherein the first quantity is less than the second quantity, wherein a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, and the KCNQ1 genotype not associated with an increased risk of QT prolongation is non-CC at position 78927 of SEQ. ID. 1. |
地址 |
Washington DC US |